Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

First Oral Option for Dermatomyositis Gets FDA Green Light



(MedPage Today) — The FDA approved the first oral treatment option for the autoimmune disorder dermatomyositis.
Brepocitinib (Lisraya) is indicated for adults with the rare condition, which causes chronic inflammation, progressive muscle weakness…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments